Opportunity Information: Apply for PAR 25 156
Apply for PAR 25 156
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.350.
- This funding opportunity was created on 2024-12-10.
- Applicants must submit their applications by 2026-09-28. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH is offering a limited-competition grant opportunity called "Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)" (Funding Opportunity Number: PAR-25-156). This program supports targeted, high-impact Specialized Innovation Programs (SIPs) that are meant to strengthen and modernize clinical and translational science capabilities within existing, awarded UM1 Clinical and Translational Science Awards (CTSA) Program Hubs. In practical terms, the opportunity is designed for CTSA hubs that can build and demonstrate a distinctive capability, research platform, or shared resource that removes a major bottleneck or addresses a clearly defined gap area in the clinical and translational research process, and can do so on a timely, actionable schedule rather than as a long-horizon concept.
The main goal of these SIP awards is not just to create something useful locally, but to develop innovations that can be proven in real hub operations and then serve as a foundation for future adoption or dissemination to other CTSA Program Hubs. Applicants are expected to show how their proposed platform or resource is "high impact" in the sense that it meaningfully improves the effectiveness, quality, speed, reliability, or scalability of clinical and translational science activities. Because the emphasis is on development and demonstration, proposals should be positioned as practical solutions to identifiable roadblocks, with a clear plan for implementation, testing in a real-world hub environment, and generation of evidence that the innovation works and can be transferred or scaled beyond the originating hub.
The funding mechanism is an NIH grant using the RC2 activity code, and clinical trials are optional, meaning projects may include a clinical trial component if it is scientifically appropriate, but a clinical trial is not required. The awarding agency is the National Institutes of Health (NIH), and the activity falls under the broad health category with CFDA number 93.350. The opportunity is categorized as discretionary funding.
Eligibility is restricted, consistent with the "limited competition" label. The eligible applicant type listed is public and state-controlled institutions of higher education, and the program is intended for institutions that are already awarded UM1 CTSA hub grants (referenced as PAR-24-272). Foreign eligibility is explicitly limited: non-domestic (non-U.S.) entities (foreign organizations) are not eligible to apply, and non-domestic components of U.S. organizations are also not eligible to apply. However, foreign components may be allowed as defined in the NIH Grants Policy Statement, which generally means certain collaborations or project elements conducted outside the U.S. can be included when they meet NIH policy requirements and are well-justified, even though the applicant institution itself must be domestic and eligible.
Key administrative details from the source information include an original closing date of 2026-09-28 and a creation date of 2024-12-10. The award ceiling and expected number of awards are not specified in the provided data, which typically means applicants should consult the full funding announcement text and any linked NIH budget guidance to understand budget limits, project period expectations, and how NIH plans to distribute awards.
Overall, this opportunity is best understood as NIH support for CTSA hubs to rapidly build and validate specialized, innovative capabilities that solve pressing operational or methodological challenges in clinical and translational science, while also producing outputs that are credible and mature enough to be adopted by other hubs in the national CTSA ecosystem.
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The opportunity is titled "Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is PAR-25-156.
Which agency is offering this grant?
The awarding agency is the National Institutes of Health (NIH).
What is the purpose of this grant program?
This limited-competition program supports targeted, high-impact Specialized Innovation Programs (SIPs) intended to strengthen and modernize clinical and translational science capabilities within existing UM1 Clinical and Translational Science Awards (CTSA) Program Hubs.
What types of projects is NIH looking to support through these SIP awards?
NIH is looking for practical, actionable innovations that can be built and demonstrated within real CTSA hub operations. Projects should create a distinctive capability, research platform, or shared resource that removes a major bottleneck or addresses a clearly defined gap in the clinical and translational research process.
What does "high impact" mean in the context of this opportunity?
"High impact" refers to innovations that meaningfully improve the effectiveness, quality, speed, reliability, or scalability of clinical and translational science activities. Applicants are expected to show that the proposed platform or resource will make a measurable difference in practice.
Is the goal to build something only for the applicant's local hub?
No. While the innovation is expected to be proven in real hub operations, the intent is for it to serve as a foundation for future adoption or dissemination to other CTSA Program Hubs.
What is meant by "development and demonstration" in this program?
The emphasis is on creating solutions that can be implemented on a timely schedule, tested in a real-world CTSA hub environment, and supported by evidence showing the innovation works and can be transferred or scaled beyond the originating hub.
What is the NIH funding mechanism for this opportunity?
The funding mechanism uses the NIH RC2 activity code.
Are clinical trials required under this funding opportunity?
No. Clinical trials are optional. A project may include a clinical trial component if scientifically appropriate, but a clinical trial is not required.
Who is eligible to apply?
Eligibility is limited. The eligible applicant type listed is public and state-controlled institutions of higher education, and the program is intended for institutions that already hold awarded UM1 CTSA hub grants (referenced as PAR-24-272).
What does "limited competition" mean here?
"Limited competition" means not all organizations can apply. This opportunity is restricted to a specific set of eligible applicants, specifically institutions that are already awarded UM1 CTSA hub grants, consistent with the CTSA hub focus of the program.
Are foreign (non-U.S.) organizations eligible to apply?
No. Non-domestic (non-U.S.) entities (foreign organizations) are not eligible to apply.
Can a U.S. organization include a non-U.S. component in its application?
No. Non-domestic components of U.S. organizations are also not eligible to apply.
Are any foreign activities allowed at all?
Foreign components may be allowed as defined in the NIH Grants Policy Statement. This typically refers to certain well-justified collaborations or project elements conducted outside the U.S. that meet NIH policy requirements, while the applicant institution itself must remain domestic and otherwise eligible.
What is the CFDA number and category for this opportunity?
The CFDA number provided is 93.350, and the opportunity falls under a broad health category.
What type of funding is this (mandatory vs discretionary)?
The opportunity is categorized as discretionary funding.
What is the application deadline?
The original closing date provided is 2026-09-28.
When was this opportunity created?
The creation date provided is 2024-12-10.
Is there an award ceiling (maximum budget) listed in the provided information?
No. The award ceiling is not specified in the provided data. Applicants typically need to consult the full funding announcement and any linked NIH budget guidance for budget limits.
Does the provided information state how many awards NIH expects to make?
No. The expected number of awards is not specified in the provided data.
What kinds of outcomes should applicants be prepared to show?
Based on the program description, applicants should be prepared to demonstrate implementation in real hub operations, testing/validation in a real-world environment, and evidence that the innovation improves clinical and translational research processes and can be transferred or scaled beyond the originating hub.
How should the timeline or scope of the proposed work be positioned?
The opportunity emphasizes timely, actionable schedules rather than long-horizon concepts. Proposals should be positioned as practical solutions to identifiable roadblocks with a clear plan for implementation and demonstration.
What is a simple way to describe this opportunity to stakeholders?
This is NIH support for existing UM1 CTSA hubs to rapidly build and validate specialized innovations (platforms, capabilities, or shared resources) that fix real bottlenecks in clinical and translational science, with the expectation that successful solutions can be adopted by other hubs.
Browse more opportunities from the same category: Health
Next opportunity: U.S. Embassy Buenos Aires PAS Strategic Programs
Previous opportunity: FY25 IIJA/IRA Bureau of Land Management California Threatened and Endangered Species Program
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 25 156
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 25 156) also looked into and applied for these:
| Funding Opportunity |
|---|
| Deriving Common Data Elements from Real-World Data for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (U24 Clinical Trial Not Allowed) Apply for RFA AG 25 001 Funding Number: RFA AG 25 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| USAID Community Health Activity Apply for 72062025RFA00003 Funding Number: 72062025RFA00003 Agency: Nigeria USAID-Abuja Category: Health Funding Amount: $35,000,000 |
| Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) Apply for PAR 25 028 Funding Number: PAR 25 028 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional) Apply for PAR 25 155 Funding Number: PAR 25 155 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) Apply for PAR 25 029 Funding Number: PAR 25 029 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed) Apply for RFA AI 24 080 Funding Number: RFA AI 24 080 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Request For Infromation - Risk Communication and Community Engagement in Global Health Security Apply for 72011925RFI00001 Funding Number: 72011925RFI00001 Agency: Tajikistan USAID-Dushanbe Category: Health Funding Amount: Case Dependent |
| Global Health Security Apply for 72049223APS00001 6 Funding Number: 72049223APS00001 6 Agency: Philippines USAID-Manila Category: Health Funding Amount: $21,600,000 |
| Integrated Health Initiative (IHI) Activity Apply for 72030625RFA00001 Funding Number: 72030625RFA00001 Agency: Afghanistan USAID-Kabul Category: Health Funding Amount: $92,500,000 |
| Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed) Apply for PAR 25 247 Funding Number: PAR 25 247 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| USAID Nigeria Global Health Security Activities Apply for 72062025RFA00005 Funding Number: 72062025RFA00005 Agency: Nigeria USAID-Abuja Category: Health Funding Amount: $32,500 |
| HIV Prevention Among Adolescent Girls and Young Women and Other Vulnerable Youth Populations - DREAMS North Apply for 72067425RFA00001 Funding Number: 72067425RFA00001 Agency: South Africa USAID-Pretoria Category: Health Funding Amount: $58,000,000 |
| Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional) Apply for RFA HL 25 011 Funding Number: RFA HL 25 011 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| NIDCD Research Grants for Translating Basic Research into Clinical Practice (R01 Clinical Trial Optional) Apply for RFA DC 25 002 Funding Number: RFA DC 25 002 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional) Apply for RFA HG 25 009 Funding Number: RFA HG 25 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Research Opportunities for New Investigators to Promote Workforce Development (R01 Clinical Trial Optional) Apply for RFA DC 25 004 Funding Number: RFA DC 25 004 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) Apply for PAR 25 032 Funding Number: PAR 25 032 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Partners Initiative Translational HIV Research for Innovative Vaccines Ecosystem (NPI THRIVE) Apply for 7200AA25RFA00001 Funding Number: 7200AA25RFA00001 Agency: Agency for International Development Category: Health Funding Amount: $98,500,000 |
| Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed) Apply for PAR 25 326 Funding Number: PAR 25 326 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed) Apply for PAR 25 315 Funding Number: PAR 25 315 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 25 156", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.